In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Arlauckas et al., 2017
In the citing paper
“Most recently, a study revealed another unexpected resistance mechanism to anti-PD-1 therapy in mice whereby tumor-associated macrophages removed the therapeutic antibody from the surface of the T cells in vivo, thus making them once again susceptible to inhibitory signaling through the receptor.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
In the citing paper
“This phenomenon could be partially overcome by administration of Fc-receptor blocking agents prior to treatment (114).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cited by
Items 601–673 of 673
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.22538878
Immunomodulation under the lens of real‐time in vivo imaging
Bousso, P., & Grandjean, C. L. (2023) · European Journal of Immunology · doi:10.1002/eji.202249921
“Impor-tantly, removing glycans present on the anti-PD1 mAb Fc portion also improved antibody activity [53].”
BackgroundYu, Y., Li, Z., Cheng, P., Jia, G., & Lu, C. (2023) · International Journal of Computational Intelligence Systems · doi:10.1007/s44196-023-00255-0
“Recently, tumor-associated macrophages were demonstrated to directly limit PD-1 blockade by removing anti-PD-1 antibodies from PD-1 + CD8 + T cells in an FcgR-dependent manner [28].”
BackgroundRemaily, B., Lathrop, H., Thomas, J. W., Kim, K., Vu, T. T., Stanton, C., Manna, M., Granchie, L., Xie, Z., Guo, Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-sitc2023.0746
Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicityPreprint
Farhat-Younis, L., Na, M., Zarfin, A., Santana-Magal, N., Richter, A., Khateeb, A., Gutwillig, A., Rasoulouniriana, D., Gleiberman, A., Beck, L., et al. (2023) · eLife · doi:10.7554/elife.91999.1
CTLA-4 Inhibitors for the Treatment of Lung Cancer
Bhatt, S., Sharma, S., Patil, S., & Pujari, R. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_6
Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicityPreprint
Farhat-Younis, L., Na, M., Zarfin, A., Khateeb, A., Santana-Magal, N., Richter, A., Gutwillig, A., Rasoulouniriana, D., Gleiberman, A., Beck, L., et al. (2024) · eLife · doi:10.7554/elife.91999.2
Immunothérapie des cancers par anticorps anti-PD-1
Guérin, M. V., Ruggiu, M., & Bousso, P. (2024) · médecine/sciences · doi:10.1051/medsci/2024088
Naei, V. Y., Tubelleza, R., Monkman, J. H., Sadeghirad, H., Donovan, M. L., Blick, T., Wicher, A. Z., Bodbin, S. E., Stad, R. K., Cooper, C. L., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5398442/v1
A bioengineered antibody conjugate reshape dendritic cell viability for immune-tolerance modulation
Chen, X., Wang, Y., Xu, T., Liu, H., Ye, X., Wang, P. G., Qin, X., Yang, S., Ning, W., Zeng, H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160431
Dongsar, T. T., Bajaj, K., Dongsar, T. S., Ali, A., Hasan, N., & Ahmad, F. J. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096349248250113093025
Tumor‐Associated Macrophages Write the Script of Cancer Obesity Paradox
Sharma, A., & Mishra, A. K. (2025) · BioEssays · doi:10.1002/bies.202400264
“Given the suppressive role of PD-1 on TAMs [9], the researchers explored whether blocking PD-1 could reverse these effects and restore macrophage-mediated anti-tumor immunity.”
Chenhui, 余. Y., Guanyi, 朱. Z., & Fei, 何. H. (2025) · Laser & Optoelectronics Progress · doi:10.3788/lop251160
Mechanisms Underlying Tumor-Associated Macrophages (TAMs)-Facilitated Metastasis
Aleebrahim‐Dehkordi, E., Deravi, N., Fallahi, M. S., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_66 · Cited by 1
Genetic and Epigenetic Indicators Predicting Response to Immune Checkpoint Inhibitors
Yang, J., Wang, B., Sun, Q., & Cai, D. (2025) · Bulletin of pioneering researches of medical and clinical science · doi:10.51847/jv5favsxwc
Zhou, Y., Liu, S., Zheng, S., Han, J., Huang, H., & Kong, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1671018
Lai, J., & Chen, H. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0114
Ding, J., Huang, X., Yao, W., & Lin, T. (2026) · Discover Oncology · doi:10.1007/s12672-026-05557-1
“M2 macrophages can also undermine ICB efficacy by forming T-cell–exclusionary niches and scavenging anti-PD-1 antibodies via Fcγ receptors [37, 38].”
李, 艳. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123663
Harrasser, M., Gohil, S. H., Lau, H. E., Peruta, M. D., Muczynski, V., Patel, D., Miranda, E., Grigoriadis, K., Grigoriadis, A. E., Granger, D., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001204
Woo, S. J., Kim, Y., Kang, H.-J., Jung, H., Youn, D. H., Hong, Y., Lee, J. J., & Hong, J. Y. (2024) · Figshare · doi:10.6084/m9.figshare.25779383
Wang, K., Xiang, Y.-J., Yu, H., Cheng, Y.-Q., Feng, J.-K., Liu, Z.-H., Shan, Y.-F., Zheng, Y.-T., 倪谦枝, & Cheng, S.-Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630386
Woo, S. J., Kim, Y., Kang, H.-J., Jung, H., Youn, D. H., Hong, Y., Lee, J. J., & Hong, J. Y. (2024) · Figshare · doi:10.6084/m9.figshare.25779494
Woo, S. J., Kim, Y., Kang, H.-J., Jung, H., Youn, D. H., Hong, Y., Lee, J. J., & Hong, J. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26717778
Woo, S. J., Kim, Y., Kang, H.-J., Jung, H., Youn, D. H., Hong, Y., Lee, J. J., & Hong, J. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26717784
Wang, K., Xiang, Y.-J., Yu, H., Cheng, Y.-Q., Feng, J.-K., Liu, Z., Shan, Y.-F., Zheng, Y.-T., 倪谦枝, & Cheng, S.-Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630389
Martin, S., Wendlinger, L., Zitti, B., Hicham, M., Postupalenko, V. Y., Marx, L., Giordano-Attianese, G., Cribioli, E., Irving, M. B., Litvinenko, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26943633
Wang, K., Xiang, Y.-J., Yu, H., Cheng, Y.-Q., Feng, J.-K., Liu, Z., Shan, Y.-F., Zheng, Y.-T., 倪谦枝, & Cheng, S.-Q. (2024) · Figshare · doi:10.6084/m9.figshare.26630392
Woo, S. J., Kim, Y., Kang, H.-J., Jung, H., Youn, D. H., Hong, Y., Lee, J. J., & Hong, J. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26717781
IFI16/IFI202 blockade suppresses tumor growth through CD8+ T-cell–mediated immunity
Lim, G. Y., Ka, N., Kim, S.-S., & Lee, M.-O. (2026) · Breast Cancer Research · doi:10.1186/s13058-025-02213-4
“TAMs can sequester anti-PD-1 antibodies via Fcγ receptors on their surface, thereby reducing their availability to PD-1 + T-cells [25].”
Tuerxun, K., Ji, W., Tukebai, T., Liu, D., Zhao, J., & Wang, Y. (2026) · SAGE Open Medicine · doi:10.1177/20503121251386139
“Particularly in patients for whom conventional radiotherapy and chemotherapy are ineffective, TAMs can limit the efficacy of immune checkpoint blockade, 20 indicating that TAMs may be one of the novel targets for future tumor treatment.”
Research progress on the correlation between OPN and immune escape of gastric cancer
Qu, F., Wu, S., & Yu, W. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02075-w
Kroemer, M. (2018) · theses.fr (ABES) · doi:10.70675/f4ebb828z8a7ez47e9zbb78z4453ed026df3
Champiat, S. (2019) · theses.fr (ABES) · doi:10.70675/e358773dz1898z4feezbb3bzbdee7c7f20a6
Role du microbiote intestinal et avec anticorps anti-PD1 induit immunesurveillance du cancer du rein
Derosa, L. (2019) · theses.fr (ABES) · doi:10.70675/e3d7f456z3645z487az8659zc864d2b57698 · Cited by 1
Anquetil, C. (2021) · theses.fr (ABES) · doi:10.70675/dce475d2z4b83z4647z85aczea2eb971762b
Etude des mécanismes permettant la croissance des métastases de mélanome
Stubbs, E. (2021) · theses.fr (ABES) · doi:10.70675/bfc19e04zc0b1z4149za281z741dd849ce2c
Garralda, E., Markert, C., Moreno, V., Calvo, E., Rohrberg, K., Kim, T. M., Lee, D. H., Cohen, J. E., Lim, W., Thistlethwaite, F. C., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4478 · Cited by 2
Ruggiu, M. (2023) · theses.fr (ABES) · doi:10.70675/de84e089z4e46z475dz8d12z25950ab6f427
Challenges in tracer development for tumor microenvironment (TME) imaging
Martin, S., Wendlinger, L., Koch, H., Lopez-Martinez, I., Corsanici, G., Battistini, G., Bonvin, Y., Delage, J. A., Viertl, D., Faizova, R., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07836-z
“An additional challenge lies in the binding of (radiolabeled) antibodies to Fcγreceptors on TAMs [154], precluding a clear distinction between macro-phage-mediated antibody uptake and specific signal stem - ming from actual target-binding in the TME.”
Optical and Photoacoustic Imaging
Napp, J., Markus, M. A., & Alves, F. (2026) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-032-15314-2_15
Pensado‐López, A., Sánchez, A. R., & Torres, F. (2025) · Springer handbooks · doi:10.1007/978-3-032-01636-2_25
Microenvironmental and Metabolic Factors in Tumor Progression: A Precision Medicine Perspective
Yerraguntla, H., Bhamidipaty, D. L., Yerraguntla, J., Fayaz, S. M., Peers, C., & Botchu, R. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_9
Miura, Y., Jikuya, R., Saijo, A., Yano, H., Kinowaki, K., Takemura, K., Uchino, K., Hasumi, H., & Komohara, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013940
Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance
Zhang, J., Tufail, M., Deng, Y., Ling, H.-J., Peng, L., Wu, J., Zeng, D., Zhang, Y., He, L., Peng, H., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101432
Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective
Wu, J., Zhou, D., Jiang, K., Li, Z., Yao, Y., Rao, S., Yang, X., & Luo, D. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00956-2
Weber, P. A. A., Perro, M., Nicolini, V., Hatje, K., Jenni, S., Briner, S., Bommer, E., Tanner, M., Pilet, S., Hüsser, T., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0207 · Cited by 1
“Another important sink which has been described for IgG1-and IgG4-based anti–PD-1 therapies is the tumor-associated macrophage– mediated drug shaving (37).”
InfluentialToumi, R., Guenette, S., & Oda, S. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1819470
“…M2 − polarized tumor − associated macrophages can promote resistance to PD − 1 blockade by using Fc g receptors to capture therapeutic anti − PD − 1 antibodies from PD − 1 + T cells, thereby reducing PD − 1 occupancy by the drug and allowing inhibitory PD − 1/PD − L1 signaling to resume (79, 80).”
Wang, Y., Cui, S., Hu, H., Yang, X., Zhao, C., Sun, L., Cao, Q., Xuan, R., Chen, H., Qin, W., et al. (2026) · Microchimica Acta · doi:10.1007/s00604-026-08256-4
Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance
Oldham, R. J., Mårtensson, L., Semmrich, M., Yoosuf, N., Holmkvist, P., Graham, L. V., Taylor, M. C., Cleary, K. L. S., Yazdani, M., Buckingham, J. F., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03785-5
“On the other hand, some studies indicate a harmful role for FcγRs in the efficacy of αPD-1 antibodies, with conflicting reports on the roles of activating and inhibitory FcγRs [12, 18–20].”
Alimohammadi, M., Mirnejad, A. M., Farahani, N., Hedayati, N., & Hushmandi, K. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06566-x
“Recent studies are focusing clinical use of tislelizumab, an engineered anti-PD-1 antibody engineered to lack FcγR binding capacity (Arlauckas, et al. 2017).”
Avraham, Y., Barth, N., Bar-On, T. Y., Toval, B., Menachem, A. H., Blanga, J., Herzog, E., Rotem, H., Itai, Y. S., Feferman, T., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01207-1
“This possibly suggests a FcγR-mediated internalization of the anti-GITR mAbs by tumor macrophages, as previously suggested for anti-PD1 mAbs 33 .”
Li, C., Li, M., Wu, X., Wu, X., Gao, H., Zhong, X., Yang, X., Hao, F., Li, C., & Wang, Q. (2026) · Biomaterials Science · doi:10.1039/d6bm00678g
Drug resistance in cancer radiotherapy: From mechanisms to overcoming strategies
Chen, Y., Cai, C., Xu, X.-C., Yang, Z., Li, J., Pan, Q., Wang, L., Luo, W., Chen, Z., Zeng, L., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108380
Argemí, J., & Campani, C. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.004
Next-generation macrophage engineering in cancer therapy: From TAM reprogramming to CAR-macrophages
Nilova, O., & Zajakina, A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103060
“3,4 TAMs frequently constitute 30%–50% of the cellular mass of solid tumors and correlate with poor prognosis across cancer types.”
Resistance to PD-1/PD-L1 blockade: Mechanism and pharmacological strategies
Kim, A. M. J., Lee, N., Chen, H., & Lim, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108404
“These design choices are central to the next generation of checkpoint biologics [61].”
Pan, J., Li, B., Lau, L. Y., Hong, Z., & Chen, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189702 · Cited by 2
Sun, X., Chu, C., & Wang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1919263
“…they can alter the spatial distribution of T cells (Peranzoni et al., 2018), influence antibody disposition through Fc-receptor-dependent capture (Arlauckas et al., 2017), regulate antigen presentation, and shape cytokine networks that determine the efficacy of immune checkpoint blockade (Yang…”
Wang, X.-L., Jiang, Z., Lu, Q., & Fang, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1960553
Benschop, R. J., TUTTLE, J. L., Emery, P., Preuß, C., Chang, C.-Y., Wang, E. B., Perumal, N. B., Sims, J. T., Dow, E. R., Nirula, A., et al. (2026) · The Lancet Rheumatology · doi:10.1016/s2665-9913(26)00218-3
Rana, J. N., & Mumtaz, S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101295
“Macrophage IL-10 can suppress dendritic-cell IL-12 and weaken CD8 + T-cell responses [34]; macrophages can restrict T-cell access to tumor nests [37]; PD-1-expressing TAMs can show impaired phagocytosis [38]; and TAMs can mediate antibody redistribution or resistance during anti-PD-1 therapy [39].”
Survival by design: Cell fate dynamics in classical Hodgkin lymphoma
Seleusan, M., Cenariu, D., Gulei, D., Kegyes, D., Țigu, A. B., Riaz, S., Zdrenghea, M., & Tomuleasa, C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105651
Smith-Salzberg, B., Salgado, L. R., Yu, C., Arons, D., Murphy, N. J., Nehlsen, A. D., Hsieh, K., & Sindhu, K. K. (2026) · Biology · doi:10.3390/biology15201851
“In one study, tumor-associated macrophages were shown to directly remove anti-PD-1 antibodies from the surface of T cells, providing another potential mechanism of resistance [116].”
Preparation of mouse tumor slices for ex vivo two-photon microscopy
Kwok, T., & Lancaster, J. N. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104915
Viatore, M., Polidori, R., Mantovani, A., & Marchesi, F. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100167
Metadata
- Authors
- Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
- Massachusetts General Hospital (US)
- Corresponding author
- Arlauckas, Sean P.
- Garris, Christopher S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-10
- Volume
- 9
- Issue
- 389
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5734617
- OpenAlex
- W2612649234
- Cited by
- 669
- References
- 55
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 76 · 2023: 75 · 2022: 84 · 2021: 98 · 2020: 87 · 2019: 62 · 2018: 50 · 2017: 29
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- National Institutes of Health (award301192, 5P50CA086355, award301190, R01AI084880, award301193, R21CA190344, award301191, U54-CA151884)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cell activation, tumor regression, in vivo imaging, target engagement
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunotherapy, Mice, Inbred C57BL, Receptors, IgG, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.